- Home
- BKE vs CELC Comparison
BKE vs CELC Comparison
Compare BKE & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKE
- CELC
- Stock Information
- Founded
- BKE 1948
- CELC 2011
- Country
- BKE United States
- CELC United States
- Employees
- BKE N/A
- CELC N/A
- Industry
- BKE Clothing/Shoe/Accessory Stores
- CELC Medical Specialities
- Sector
- BKE Consumer Discretionary
- CELC Health Care
- Exchange
- BKE Nasdaq
- CELC Nasdaq
- Market Cap
- BKE 2.8B
- CELC 2.3B
- IPO Year
- BKE 1992
- CELC 2017
- Fundamental
- Price
- BKE $55.65
- CELC $71.50
- Analyst Decision
- BKE Hold
- CELC Strong Buy
- Analyst Count
- BKE 1
- CELC 5
- Target Price
- BKE $54.00
- CELC $67.20
- AVG Volume (30 Days)
- BKE 494.3K
- CELC 1.1M
- Earning Date
- BKE 11-21-2025
- CELC 11-13-2025
- Dividend Yield
- BKE 7.18%
- CELC N/A
- EPS Growth
- BKE N/A
- CELC N/A
- EPS
- BKE 4.00
- CELC N/A
- Revenue
- BKE $1,250,675,000.00
- CELC N/A
- Revenue This Year
- BKE $7.09
- CELC N/A
- Revenue Next Year
- BKE $2.91
- CELC N/A
- P/E Ratio
- BKE $13.59
- CELC N/A
- Revenue Growth
- BKE 1.62
- CELC N/A
- 52 Week Low
- BKE $33.12
- CELC $7.58
- 52 Week High
- BKE $61.69
- CELC $63.06
- Technical
- Relative Strength Index (RSI)
- BKE 47.08
- CELC 76.13
- Support Level
- BKE $52.67
- CELC $49.80
- Resistance Level
- BKE $54.10
- CELC $83.00
- Average True Range (ATR)
- BKE 1.27
- CELC 4.07
- MACD
- BKE -0.16
- CELC 2.18
- Stochastic Oscillator
- BKE 51.29
- CELC 71.88
About BKE Buckle Inc. (The)
Buckle Inc is a retailer of casual apparel, footwear, and accessories. The company retails medium to affordable priced casual apparel, footwear, and accessories for fashion-conscious young men and women. It retails under the brand names 'Buckle' and 'The Buckle'. Buckle markets a wide selection of mostly brand-name casual apparel including denim, other casual bottoms, tops, sportswear, outerwear, accessories, and footwear.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.